黄连素抗食管癌EC109细胞的作用及其机制  

Inhibition of berberine on EC109 cells in esophageal cancer and its machanism

作　　者：刘红岗[1] 赖远阳[1] 朱以芳[1] 同李平[1] 董小平[1] 许娟 张勇[1] 郭海华[1] 李小飞[1] 闫小龙[1] 

机构地区：[1]第四军医大学唐都医院胸外科,西安710038

出　　处：《临床与病理杂志》2017年第12期2524-2529,共6页Journal of Clinical and Pathological Research

摘　　要：目的:研究黄连素(berberine,BBR)的抗食管癌作用及其机制。方法:给予50,100,200μmol/L BBR处理EC109细胞24 h,检测EC109细胞的活力及迁移能力。Western印迹检测pAkt,蛋白激酶B(protein kinase B,Akt),叉头转录因子O3(forkhead Class box O3,FOXO3),B淋巴细胞瘤-2(B-cel l lymphoma-2,bcl-2)及Bax的表达水平,特别是FOXO3的细胞核转位情况。建立裸鼠皮下肿瘤模型,腹腔注射BBR,明确BBR的抗食管癌作用。结果:BBR处理EC109细胞后,细胞活力下降,划痕实验检测细胞间距增大(P<0.05)。BBR降低了Akt的磷酸化水平,pAkt/总Akt下降;细胞质内的FOXO3下降;细胞核内的FOXO3升高;bcl-2表达水平下降;Bax则显著升高。在体研究发现BBR剂量依赖地抑制了肿瘤生长。结论:BBR能显著抑制食管癌EC109细胞的增殖、迁移以及在体增殖能力,该作用可能是通过抑制Akt磷酸化水平、增加FOXO3细胞核转位进而促进细胞凋亡来实现的。Objective： To investigate the role of berberine （BBR） on esophageal cancer and its mechanism. Methods： EC109 cells were treated with 50, 100, 200 μmol/L BBR and the CCK8 assay and cell migration assay were conducted. Further, we detected the phosphorylation level of Akt, the location of FOXO3, B-cell lymphoma-2 （bcl-2） and Bax expression through Western blot. To further evaluate whether BBR has an anti-tumor growth effect in vivo, we measured the tumor volume in a tumor bearing model by transplanting EC109 cells into nude mice. Results： After treated by BBR, EC109 cell viability was significantly reduced compared with the control group （P〈0.05）. Distance between cell boundary was significantly increased, indicating a worse migration ability （P〈0.05）. Compared with the control group, pAkt expression/total Akt expression was significantly decreased after BBR treatment. Cytoplasmic FOXO3 decreased and nucleus FOXO3 increased. Bcl-2 was decreased and Bax was increased by BBR. In vivo study showd that tumor volumes in nude mice were significantly reduced after BBR treatment. Conclusion： BBR can inhibit EC109 cell growth and induce cell apoptosis, which might be mediated by regulation of Akt/FOXO3 pathway.

关 键 词：黄连素 食管癌 蛋白激酶B 叉头蛋白转录因子3 细胞核转位 细胞凋亡 

分 类 号：R735.1[医药卫生—肿瘤]